ARTIDIS
ARTIDIS is a Basel-based medtech company that has developed an atomic force microscopy platform with AI-powered analytics (ArtidisNet) to measure nanomechanical properties of tumor tissue, serving oncology healthcare providers, academic researchers, and pharmaceutical companies across the US and EU markets.
- Company typePrivate
- Founded2011
- HeadquartersBasel, Switzerland
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What ARTIDIS does
ARTIDIS is a Basel, Switzerland-headquartered medical technology company founded in 2011 as a spin-off from the University of Basel, with operational hubs in Houston, Texas and Barcelona, Spain. The company has developed a proprietary nanomechanical tissue analytics platform based on atomic force microscopy (AFM) that measures physical properties—stiffness, viscosity, and adhesion—of tumor tissue and the tumor microenvironment at the nanoscale. Its AI-powered cloud analytics platform, ArtidisNet, integrates these mechanical measurements with molecular, clinical, histopathological, genomic, and imaging data to produce quantitative biomechanical profiles that predict metastatic potential and inform treatment selection, with results available within hours at the point of care.
The company's portfolio spans the ARTIDIS System (investigational-use core platform), the ARTIDIS Research Device (automated benchtop unit for research and clinical research settings), the NEO-Match clinical application (currently undergoing clinical validation across multiple tumor types for assessing cancer cell deformability and microenvironment barriers), ArtidisNet (multimodal data integration platform), and service offerings including Core Lab sample testing and Augmented Cancer Research for therapy development support. ARTIDIS distributes its technology through direct enterprise field sales to major cancer centers and academic medical centers, a core lab sample-testing service available to US and EU customers, and joint clinical collaboration programs.
ARTIDIS serves three primary customer segments: oncology healthcare providers seeking faster diagnosis and treatment optimization beyond genomics and pathology; academic cancer researchers studying mechanobiology and novel biomarkers; and pharmaceutical/biotech companies pursuing companion diagnostics and therapy development. Revenue mechanics span hardware sales (device installation), professional services (sample testing), and emerging recurring clinical applications (NEO-Match). The company is currently pre-commercial for clinical diagnostic use, with all clinical outputs designated for investigational or research use only pending regulatory clearance.
ARTIDIS firmographics
Firmographics- Name
- ARTIDIS
- Legal name
- ARTIDIS AG
- Website
- https://artidis.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- ARTIDIS is a Basel-based medtech company that has developed an atomic force microscopy platform with AI-powered analytics (ArtidisNet) to measure nanomechanical properties of tumor tissue, serving oncology healthcare providers, academic researchers, and pharmaceutical companies across the US and EU markets.
- Ownership category
- akta.pro rank
ARTIDIS industry classification
Industry- Product category
- Cancer Diagnostics and Treatment Optimization
- NAICS
- Research and Development in Nanotechnology (541713), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where ARTIDIS is headquartered
LocationHeadquarters
- HQ city
- Basel
- HQ country
- Switzerland
- HQ region
- Europe
Offices3 records
Markets served
ARTIDIS business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Device Sales/Installation: Artidis installs its automated nanomechanical profiling platform in partner labs and clinics. Research institutions and clinical facilities can acquire the Artidis device for their own use.
- Core Lab Services - Sample Testing: Ship samples to Artidis facilities (Houston, Basel, Barcelona) and receive full biomechanical profiles within days. Available for US and EU customers only. Targets academic and industry labs seeking biomechanical data.
- NEO-Match Assessment: Clinical product for assessing cancer cell deformability and tumor microenvironment prior to therapy. Currently undergoing clinical validation in multiple tumor types. Characterizes cellular deformability and microenvironment barriers.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
ARTIDIS product offering
Product offeringCore offering
ARTIDIS develops and commercializes a nanomechanical tissue analytics platform based on atomic force microscopy (AFM) that measures physical properties (stiffness, viscosity, adhesion) of tumor tissue and the tumor microenvironment to predict metastatic potential and guide cancer treatment decisions. The company offers the ARTIDIS System and ARTIDIS Research Device hardware platforms, the AI-powered ArtidisNet cloud analytics platform, the NEO-Match clinical assessment application, and core lab sample-testing services for cancer centers, academic researchers, and pharmaceutical companies.
Product overview
ARTIDIS offers a unified nanomechanical tissue analytics platform centered on the ARTIDIS® System using proprietary atomic force microscopy (AFM) technology. The platform measures physical properties (stiffness, viscosity, adhesion) of tumors and tumor microenvironments to predict metastatic potential and guide treatment decisions, with results available within hours. The ARTIDIS Research Device provides automated, AI-assisted AFM for research and clinical use. Artidisnet serves as the AI-powered cloud integration platform that combines nanomechanical measurements with molecular, clinical, imaging, and patient metadata data for comprehensive analytics. Clinical applications include the NEO-Match® assessment for cancer cell deformability and microenvironment barriers. Services include Core Lab Services for sample analysis and Augmented Cancer Research for therapy development support. The platform is tumor-agnostic with validation across breast, lung, pancreas, liver, bladder, and sarcoma cancers.
Differentiator
Problem solved
Functional benefit
Products and services
- ARTIDIS System The core nanomechanical profiling platform using atomic force microscopy (AFM) technology to measure physical properties (stiffness, viscosity, adhesion) of tumor tissue and tumor microenvironment, providing same-day results at point of care while preserving tissue integrity for downstream pathology analysis. For investigational use in cancer centers and clinical research facilities.
- ARTIDIS Research Device Automated, AI-assisted atomic force microscopy platform for everyday research with subcellular resolution, built-in cloud analytics, high-throughput assays, and seamless scaling from benchtop to clinical research. Targets research institutions and labs.
- ArtidisNet AI-powered cloud platform that integrates nanomechanical measurements with molecular, clinical, histopathology, genomics, imaging, and patient metadata, providing real-time collaboration, advanced analytics, and seamless data management from measurement to treatment decision.
- NEO-Match Clinical assessment of cancer cell deformability and tumor microenvironment (TME) prior to therapy, characterizing cellular deformability (softness/stiffness correlating with metastatic potential) and microenvironment barriers influencing treatment penetration. Undergoing clinical validation in multiple tumor types.
- Core Lab Services Send-sample service providing high-resolution biomechanical data with fast turnaround and scientific team support. Accepts cells, hydrogels, organoids, preclinical tissues, and fresh clinical biopsies; available to US and EU academic and industry labs.
- Augmented Cancer Research Research service that adds a biomechanical layer to therapy development by identifying novel mechanical biomarkers, understanding treatment resistance, and improving model predictivity through measurement of tumors in their complete microenvironment. Supports chemotherapy, CAR T-cell/IO therapy, and radiotherapy research.
- Biomechanical Phenotyping Service bringing AFM to routine point-of-care use, profiling cells in their native microenvironment quickly and reproducibly. Assays preserve tissue integrity during measurement while generating quantitative mechanical profiles for cancer centers and clinical laboratories.
- Multimodal Patient Data Integration Service that transforms nanomechanical data into clinically meaningful insights by integrating mechanical profiles with histopathology, genomics, imaging, and patient metadata, enabling seamless data management, real-time collaboration, and advanced analytics.
Quantifiable outcome
- 92% sensitivity, 100% specificity, 95% accuracy in differentiating treatment response groups in CAR-T + LDRT study
- +2 more outcomes
Companies that use ARTIDIS
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles3 records
ARTIDIS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
ARTIDIS partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Baylor College of MedicinecoreBaylor College of Medicine leads the global ANGEL (Artidis Nanomechanical Generated Measurements for Early Lesions) study with over 2,700 participants. Dr. Alastair Thompson serves as lead investigator. Baylor St. Luke's Medical Center and Harris Health Smith Clinic serve as initial US recruitment sites for breast cancer validation.
- UT Southwestern Medical CentercoreParticipating site in the global ANGEL breast cancer study, integrating biomechanical profiling into breast cancer care alongside MD Anderson and Baylor College of Medicine.
- Vall d'Hebron University HospitalcoreEuropean recruitment site for the ANGEL study in Barcelona, Spain. Collaborates with Artidis to validate nanomechanical profiling for breast cancer diagnosis and treatment optimization.
- Claraspital BaselcoreFirst European center for ANGEL study with Dr. Rosanna Zanetti as Lead Site Investigator. Serves as primary European validation site for Artidis technology in breast cancer care.
- MD Anderson Cancer CentercoreStrategic alliance to investigate Artidis technology as a novel treatment-optimization tool for patients with solid tumors. MD Anderson and Artidis researchers collaboratively evaluate nano-scale physical properties combined with clinical data to identify biomarker signatures for optimal therapeutic approaches. Focus areas include neoadjuvant applications for chemotherapy and radiotherapy/immunotherapy.
- University of Barcelona and Hospital Clínic de Barcelonacore18-month clinical collaboration investigating nanomechanical profiling as a novel diagnostic and treatment optimization approach in non-small cell lung carcinoma (NSCLC). Teams analyze cancer tissue nanomechanical profiles combined with genetic and immune phenotypes to identify distinct signatures and predict treatment response.
- James Welsh, MD (MD Anderson)coreSponsored research agreement with Dr. James Welsh focusing on understanding immunotherapy resistance and response. Preclinical work on nanomechanical changes in response to radiation therapy and immune checkpoint inhibitor treatment in lung cancer models.
- Institute for Medical Research and Occupational HealthminorStrategic collaboration exploring nanomechanical profiling across human and animal tissues, and disease models.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
ARTIDIS competitors and assessment
Company assessmentPeers
Broad incumbents
- Bruker: Major manufacturer of atomic force microscopy and other advanced research/analytical instruments used in life sciences. Directly comparable to ARTIDIS on the underlying AFM hardware platform, though Bruker operates as a broad incumbent selling into many research workflows beyond oncology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
ARTIDIS social profiles
Digital presenceARTIDIS financial estimates
Financial estimateRevenue estimate
Valuation estimate
ARTIDIS leadership team
Management profileNumber of profiles
Profiles10 records
ARTIDIS subsidiaries and ownership
Company hierarchySubsidiaries2 records
ARTIDIS funding detail
Funding detailFunding overview
Funding rounds3 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ARTIDIS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ARTIDIS
What does ARTIDIS do?
ARTIDIS develops and commercializes a nanomechanical tissue analytics platform based on atomic force microscopy (AFM) that measures physical properties (stiffness, viscosity, adhesion) of tumor tissue and the tumor microenvironment to predict metastatic potential and guide cancer treatment decisions. The company offers the ARTIDIS System and ARTIDIS Research Device hardware platforms, the AI-powered ArtidisNet cloud analytics platform, the NEO-Match clinical assessment application, and core lab sample-testing services for cancer centers, academic researchers, and pharmaceutical companies.
Is ARTIDIS a public or private company?
ARTIDIS is a private company. It is classified as venture growth investor backed and is currently operating.
When was ARTIDIS founded?
ARTIDIS was founded in 2011. It employs 51 to 100 people.
Where is ARTIDIS based?
ARTIDIS is headquartered in Basel, Switzerland, in the Europe region.
How does ARTIDIS make money?
Three revenue lines are on record. Device Sales/Installation is the primary driver. The others are core Lab Services - Sample Testing and NEO-Match Assessment.
Who are ARTIDIS's main competitors?
JPK Instruments (Bruker Nano Surfaces) is listed as a peer. Bruker is listed as a broad incumbent.
Does ARTIDIS have an API?
No public API is recorded for ARTIDIS.
What industry is ARTIDIS in?
ARTIDIS's product category is Cancer Diagnostics and Treatment Optimization. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541713 and its SIC code is 3826.